Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CIK Cells as Adjuvant Therapy in Post-Resection HCC
NCT07709299Phase 1Not yet recruiting
- Sponsor
- Royan Institute
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous cytokine-induced killer cells in hepatocellular carcinoma (HCC), sponsored by Royan Institute. Primary endpoint: Adverse Events at 6 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
autologous cytokine-induced killer cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07709299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07709299.